MRNA vs PLTR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

MRNA

35.2
AI Score
VS
PLTR Wins

PLTR

39.4
AI Score

Investment Advisor Scores

MRNA

35score
Recommendation
SELL

PLTR

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA PLTR Winner
Revenue 534.00M 3.57B PLTR
Net Income -2.13B 1.93B PLTR
Net Margin -397.9% 54.2% PLTR
Operating Income -2.20B 1.67B PLTR
ROE -31.4% 19.8% PLTR
ROA -19.4% 16.5% PLTR
Total Assets 10.96B 11.68B PLTR
Cash 1.72B 2.03B PLTR
Current Ratio 2.29 7.23 PLTR
Free Cash Flow -1.25B 2.09B PLTR

Relative Price Performance (Last 90 Days)

MRNA 1M: +40.0% · 3M: +156.6% PLTR 1M: +14.0% · 3M: +50.4%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

PLTR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (14.2% over 20 days), RSI 66

RSI (14): 66.5 · Price: $194.12

Fundamentals Snapshot

Metric MRNA PLTR
Market Cap — —
Forward P/E -41.0 82.8
Trailing P/E — 165.6
Revenue (TTM) — —
Revenue Growth 0.0% 0.9%
Gross Margin -0.7% 0.8%
Operating Margin -5.6% 0.5%
EPS -7.36 1.16
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PLTR is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.